• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Harmony Biosciences Holdings Inc.

    11/5/25 11:35:23 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    HARMONY BIOSCIENCES HOLDINGS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    413197104

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    413197104


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,845,850.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,846,972.08
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,846,972.08
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.7 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    413197104


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,846,972.08
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,846,972.08
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    HARMONY BIOSCIENCES HOLDINGS INC
    (b)Address of issuer's principal executive offices:

    630 W Germantown Pike,Suite 215,Plymouth Meeting,PA,USA,19462
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    413197104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3846972.08
    (b)Percent of class:

    6.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    3846972.08

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of HARMONY BIOSCIENCES HOLDINGS INC. No one other person's interest in the COMMON STOCK of HARMONY BIOSCIENCES HOLDINGS INC is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:11/04/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:11/04/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $HRMY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    10/10/2024Outperform
    Raymond James
    9/10/2024$56.00Buy
    UBS
    6/21/2024$48.00Buy
    Citigroup
    More analyst ratings

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

    WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash Generation of $106M with $778M On Balance Sheet at end of Q3 2025 Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025 Potential Best-In-Class Orexin 2 Agonist (BP1.15205) On Track to Dose First Subject in Q4 2025; Phase 1 Clinical Data in 2026 Late-Stage Catalyst-Rich Pipeline Advances with up to Five Phase 3 Programs by Year End Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, In

    11/4/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over-year revenue growth These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy The company is increasing its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million Harmony to report full Q3 2025 earnings an

    10/23/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The RECONNECT Study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher than expected placebo response rate. Kumar Budur, M.D., M.S., Chief Medical and Scientific Officer at Harmony Biosciences said, "Although the study did not achieve its primary endpoint, the findings from this study provide valuable insights into Fragile X syndrome, a rare neurobehavioral condition with significant unmet medical need and no FDA-approved therapies. We will conduct a comprehe

    9/24/25 8:00:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Harmony Biosciences with a new price target

    Truist initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00

    7/21/25 8:34:40 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Harmony Biosciences with a new price target

    Goldman resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $33.00

    7/10/25 8:55:45 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Harmony Biosciences with a new price target

    Oppenheimer resumed coverage of Harmony Biosciences with a rating of Outperform and set a new price target of $61.00

    6/2/25 8:52:53 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Harmony Biosciences Holdings Inc.

    SCHEDULE 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    11/5/25 11:35:23 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.

    10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    11/4/25 8:42:17 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

    11/4/25 8:05:15 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Kapadia Sandip converted options into 45,000 shares and covered exercise/tax liability with 24,039 shares (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    10/2/25 4:05:07 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Valor Iv Pharma Holdings, Llc disposed of 6,618,033 shares, closing all direct ownership in the company (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    9/2/25 5:45:59 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Kapadia Sandip sold $787,378 worth of shares (21,573 units at $36.50), closing all direct ownership in the company (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    8/19/25 4:15:07 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

    WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash Generation of $106M with $778M On Balance Sheet at end of Q3 2025 Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025 Potential Best-In-Class Orexin 2 Agonist (BP1.15205) On Track to Dose First Subject in Q4 2025; Phase 1 Clinical Data in 2026 Late-Stage Catalyst-Rich Pipeline Advances with up to Five Phase 3 Programs by Year End Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, In

    11/4/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over-year revenue growth These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy The company is increasing its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million Harmony to report full Q3 2025 earnings an

    10/23/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

    WAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025 Phase 3 RECONNECT Study in Fragile X Syndrome (FXS) Designed to Confirm Positive Findings from the Phase 2/3 CONNECT Study; Opportunity to Address Unmet Needs of 80,000 Patients with FXS On Track to Begin First-in-Human Clinical Trial with BP1.15205, a Potential Best-In-Class Orexin-2 Agonist, in 2H 2025 Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028 Conference Call

    8/5/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

    3/24/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

    PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as

    1/6/23 4:39:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care